Genetic	O
polymorphism	O
and	O
transcriptional	O
regulation	O
of	O
CREBBP	O
gene	O
in	O
patient	O
with	O
diffuse	B-arm_description
large	I-arm_description
B	I-arm_description
-	I-arm_description
cell	I-arm_description
lymphoma	I-arm_description
Genetic	O
polymorphism	O
and	O
transcriptional	O
regulation	O
of	O
CREBBP	O
gene	O
in	O
patient	O
with	O
diffuse	B-arm_description
large	I-arm_description
B	I-arm_description
-	I-arm_description
cell	I-arm_description
lymphoma	I-arm_description
29	O
September	O
2020	O
29	O
September	O
2020	O
HaifengZhao	B-authors

P.R.	O
China	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

P.R.	O
China	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

P.R.	O
China	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

P.R.	O
China	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

P.R.	O
China	O
Department	O
of	O
Laboratory	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

P.R.	O
China	O
Department	O
of	O
Lymphoma	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

P.R.	O
China	O
Tianjin	O
P.R.	O
China	O
Genetic	O
polymorphism	O
and	O
transcriptional	O
regulation	O
of	O
CREBBP	O
gene	O
in	O
patient	O
with	O
diffuse	B-arm_description
large	I-arm_description
B	I-arm_description
-	I-arm_description
cell	I-arm_description
lymphoma	I-arm_description
29	O
September	O
2020	O
29	O
September	O
2020	O
29	O
September	O
2020	O
10.1042	O
/	O
BSR20191162	O
Received	O
:	O
23	O
April	O
2019	O
Revised	O
:	O
17	O
July	O
2019	O
Accepted	O
:	O
30	O
July	O
2019	O
Accepted	O
Manuscript	O
Online	O
:	O
31	O
July	O
2019	O

Diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
an	O
aggressive	O
non	O
-	O
Hodgkin	O
lymphoma	O
with	O
extreme	O
heterogeneity	O
,	O
accounting	O
for	O
30	O
-	O
40	O
%	O
of	O
newly	O
diagnosed	O
lymphomas	O
[	O
1	O
]	O
.	O
Although	O
the	O
standard	O
R	O
-	O
CHOP	O
regimen	O
has	O
extremely	O
good	O
therapeutic	O
effect	O
on	O
DLBCL	O
patients	O
,	O
approximately	O
30	O
-	O
40	O
%	O
of	O
patients	O
show	O
relapse	O
and	O
10	O
%	O
have	O
refractory	O
disease	O
[	O
2	O
]	O
.	O
In	O
the	O
past	O
decades	O
,	O
accumulating	O
evidences	O
have	O
shown	O
the	O
genetic	O
,	O
microenvironment	O
,	O
autoimmune	O
diseases	O
and	O
occupational	O
exposure	O
participated	O
in	O
the	O
pathogenesis	O
of	O
DLBCL	O
[	O
3][4][5	O
]	O
.	O
With	O
gene	O
-	O
expression	O
profiling	O
and	O
next	O
-	O
generation	O
sequencing	O
,	O
some	O
common	O
genetic	O
loci	O
are	O
found	O
to	O
enmesh	O
in	O
the	O
lymphomagenesis	O
of	O
DLBCL	O
[	O
6	O
]	O
.	O
However	O
,	O
the	O
pathogenesis	O
of	O
DLBCL	O
is	O
still	O
not	O
fully	O
understood	O
.	O

Single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
is	O
the	O
most	O
abundant	O
type	O
of	O
genetic	O
variation	O
that	O
occurs	O
at	O
a	O
specific	O
position	O
in	O
the	O
human	O
genome	O
.	O
Accumulating	O
evidence	O
indicated	O
that	O
SNPs	O
have	O
shown	O
the	O
ability	O
to	O
influence	O
the	O
activity	O
and	O
expression	O
of	O
the	O
genes	O
,	O
and	O
affect	O
the	O
pathogenesis	O
and	O
risk	O
of	O
an	O
extensive	O
range	O
of	O
cancer	O
[	O
7][8][9][10	O
]	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
SNPs	O
in	O
TP53	O
,	O
XRCC1	O
and	O
A20	O
are	O
related	O
to	O
the	O
risk	O
of	O
DLBCL	O
[	O
11][12][13	O
]	O
.	O
Genome	O
-	O
wide	O
association	O
studies	O
have	O
recognized	O
genetic	O
susceptibility	O
locus	O
for	O
DLBCL	O
[	O
14	O
]	O
.	O
The	O
contribution	O
of	O
SNP	O
in	O
histone	O
-	O
modifying	O
enzymes	O
to	O
DLBCL	O
pathogenesis	O
is	O
a	O
research	O
hotspot	O
.	O

Somatic	O
mutations	O
in	O
cyclic	O
AMP	O
response	O
element	O
binding	O
protein	O
(	O
CREBBP	O
)	O
and	O
EP300	O
,	O
and	O
removal	O
or	O
inactivation	O
of	O
the	O
HAT	O
coding	O
domain	O
affect	O
approximately	O
39	O
%	O
of	O
DLBCL	O
patients	O
[	O
15	O
]	O
,	O
and	O
are	O
also	O
associated	O
with	O
Rubinstein	O
Tyabi	O
Syndrome	O
(	O
RTS	O
)	O
[	O
16,17	O
]	O
.	O
CREBBP	O
belongs	O
to	O
the	O
KAT3	O
family	O
of	O
histone	O
/	O
protein	O
lysine	O
acetyltransferases	O
,	O
which	O
is	O
a	O
highly	O
conserved	O
and	O
universally	O
expressed	O
nuclear	O
phosphoprotein	O
[	O
18,19	O
]	O
.	O
CREBBP	O
inactivation	O
expedites	O
GC	O
-	O
derived	O
pathogenesis	O
of	O
lymphoma	O
[	O
20	O
]	O
.	O
Down	O
-	O
regulation	O
of	O
CREBBP	O
is	O
related	O
to	O
worse	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
in	O
pediatric	O
acute	O
lymphoblastic	O
leukemia	O
and	O
may	O
affect	O
the	O
response	O
to	O
chemotherapy	O
[	O
21	O
]	O
.	O
Crebbp	O
+	O
/−	O
mice	O
had	O
blemish	O
in	O
the	O
development	O
of	O
B	O
-	O
cell	O
lymphoid	O
and	O
an	O
increased	O
incidence	O
of	O
hematopoietic	O
malignancy	O
[	O
22	O
]	O
.	O
The	O
rs3025684	O
(	O
A	O
/	O
G	O
)	O
is	O
an	O
SNP	O
of	O
CREBBP	O
located	O
in	O
intron	O
21	O
.	O
This	O
SNP	O
was	O
shown	O
to	O
be	O
a	O
possible	O
risk	O
factor	O
for	O
developing	O
autism	O
in	O
the	O
Netherlands	O
,	O
U.K.	O
and	O
Denmark	O
,	O
as	O
well	O
as	O
among	O
Bengali	O
-	O
Hindus	O
[	O
23,24	O
]	O
.	O

However	O
,	O
the	O
status	O
of	O
CREBBP	O
rs3025684	O
SNP	O
and	O
the	O
gene	O
expression	O
in	O
DLBCL	O
in	O
a	O
Chinese	O
Han	O
population	O
is	O
not	O
completely	O
understood	O
.	O
It	O
was	O
hypothesized	O
that	O
CREBBP	O
rs3025684	O
polymorphism	O
and	O
expression	O
may	O
be	O
related	O
to	O
the	O
susceptibility	O
and	O
pathogenesis	O
of	O
DLBCL	B-arm_description
,	O
and	O
the	O
results	O
found	O
that	O
it	O
may	O
be	O
a	O
prognostic	O
factor	O
for	O
DLBCL	B-arm_description
patients	O
.	O

The	O
present	O
study	O
recruited	O
250	O
healthy	B-arm_description
individuals	I-arm_description
and	O
248	O
DLBCL	B-arm_description
patients	O
,	O
diagnosed	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
classification	O
[	O
25	O
]	O
at	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
from	O
2011	O
to	O
2013	O
.	O
Peripheral	O
blood	O
and	O
lymphoid	O
specimens	O
were	O
collected	O
before	O
initial	O
therapy	O
.	O
All	O
participants	O
signed	O
the	O
informed	O
consent	O
,	O
and	O
the	O
approval	O
of	O
the	O
study	O
was	O
obtained	O
from	O
the	O
Tianjin	O
Cancer	O
Institute	O
Institutional	O
Review	O
Board	O
.	O
The	O
clinical	O
and	O
pathological	O
characteristics	O
of	O
the	O
patients	O
and	O
controls	O
are	O
presented	O
in	O
Table	O
1	O
.	O

The	O
TIANamp	O
genomic	O
DNA	O
kit	O
(	O
TIANGEN	O
Biotech	O
,	O
Beijing	O
,	O
China	O
)	O
was	O
used	O
to	O
extract	O
the	O
genomic	O
DNA	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O
Genotypes	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
.	O
The	O
reaction	O
system	O
contained	O
60	O
ng	O
DNA	O
template	O
,	O
2	O
μl	O
of	O
each	O
primer	O
,	O
25	O
μl	O
Premix	O
Taq	O
(	O
Takara	O
,	O
Dalian	O
,	O
China	O
)	O
and	O
sterilized	O
water	O
up	O
to	O
50	O
μl	O
.	O
The	O
PCR	O
protocol	O
was	O
as	O
follows	O
:	O
initial	O
denaturation	O
at	O
94	O
•	O
C	O
for	O
5	O
min	O
,	O
followed	O
by	O
30	O
cycles	O
of	O
denaturation	O
at	O
94	O
•	O
C	O
for	O
30	O
s	O
,	O
annealing	O
at	O
58	O
•	O
C	O
for	O
30	O
s	O
,	O
extension	O
at	O
72	O
•	O
C	O
for	O
30	O
s	O
,	O
followed	O
by	O
72	O
•	O
C	O
for	O
7	O
min	O
.	O
The	O
primers	O
for	O
rs3025684	O
were	O
:	O
forward	O
5	O
-AGGGGAAACAACTCACCCTG-3	O
and	O
reverse	O
5	O
-CTGGTCTTGTGGTTCCGTGT-3	O
.	O
The	O
PCR	O
product	O
was	O
digested	O
by	O
MnlI	O
(	O
New	O
England	O
Biolabs	O
,	O
Beverly	O
,	O
MA	O
)	O
and	O
analyzed	O
by	O
gel	O
electrophoresis	O
on	O
2.5	O
%	O
agarose	O
gels	O
.	O
Randomly	O
selected	O
DNA	O
samples	O
were	O
detected	O
by	O
direct	O
sequencing	O
to	O
verify	O
the	O
results	O
(	O
Supplementary	O
Figure	O
S1	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
TRIzol	O
reagent	O
(	O
Invitrogen	O
)	O
.	O
We	O
normalized	O
the	O
levels	O
of	O
expression	O
of	O
CREBBP	O
relative	O
to	O
glyceraldehyde	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
,	O
and	O
2	O
−	O
C	O
t	O
indicated	O
the	O
quantification	O
of	O
gene	O
expression	O
.	O
The	O
primers	O
for	O
CREBBP	O
were	O
:	O
forward	O
5	O
-CGGCTCTAGTATCAACCCAGG-3	O
and	O
reverse	O
5	O
-TTTTGTGCTT	O
GCGGATTCAGT-3	O
.	O
The	O
primers	O
for	O
0	O
:	O
italic	O
GAPDH	O
/0	O
:	O
italic	O
were	O
:	O
forward5	O
-CCACATCGCTCAGACACCAT-3	O
andreverse5	O
-CCAGGCGCCCAATACG-3	O
.	O

A	O
goodness	O
-	O
of	O
-	O
fit	O
Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
analyze	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O
The	O
Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
detect	O
the	O
allelic	O
frequency	O
and	O
genotypic	O
distribution	O
in	O
all	O
subjects	O
.	O
We	O
estimated	O
the	O
relationship	O
between	O
CREBBP	O
rs3025684	O
and	O
the	O
susceptibility	O
to	O
DLBCL	B-arm_description
by	O
unconditional	O
logistic	O
regression	O
.	O
The	O
prognostic	O
factors	O
were	O
explored	O
by	O
univariate	O
Cox	O
regression	O
analysis	O
.	O
The	O
CREBBP	O
mRNA	O
expression	O
levels	O
were	O
investigated	O
by	O
the	O
independent	O
Student	O
's	O
t	O
test	O
.	O
The	O
survival	O
curves	O
were	O
computed	O
by	O
Kaplan	O
-	O
Meier	O
method	O
with	O
log	O
-	O
rank	O
tests	O
.	O
All	O
the	O
statistical	O
analyses	O
mentioned	O
above	O
were	O
executed	O
by	O
IBM	O
SPSS	O
Statistics	O
version	O
20.0	O
.	O
P<0.05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O
The	O
false	O
-	O
positive	O
report	O
probability	O
(	O
FPRP	O
)	O
was	O
calculated	O
as	O
previously	O
described	O
[	O
26	O
]	O
,	O
we	O
set	O
an	O
FPRP	O
value	O
of	O
0.2	O
and	O
assigned	O
a	O
prior	O
probability	O
of	O
0.1	O
.	O

The	O
genotypic	O
distribution	O
and	O
allelic	O
frequencies	O
showed	O
significant	O
difference	O
between	O
the	O
DLBCL	B-arm_description
patients	O
and	O
healthy	O
individuals	O
for	O
CREBBP	O
rs3025684	O
(	O
P=0.021	O
and	O
P=0.013	O
,	O
respectively	O
,	O
shown	O
in	O
Table	O
2	O
)	O
.	O
Furthermore	O
,	O
the	O
association	O
between	O
the	O
genotype	O
and	O
the	O
clinical	O
parameters	O
of	O
DLBCL	B-arm_description
patients	O
was	O
explored	O
,	O
which	O
showed	O
no	O
statistical	O
differences	O
as	O
shown	O
in	O
Table	O
3	O
.	O

The	O
GA	O
genotype	O
was	O
correlated	O
with	O
the	O
risk	O
of	O
DLBCL	B-arm_description
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.692	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
1.170	O
-	O
2.446	O
,	O
P=0.005	O
)	O
(	O
Table	O
4	O
)	O
.	O
However	O
,	O
the	O
AA	O
genotype	O
displayed	O
a	O
slightly	O
increased	O
susceptibility	O
to	O
DLBCL	B-arm_description
with	O
no	O
statistical	O
significance	O
(	O
OR	O
=	O
1.620	O
,	O
95	O
%	O
CI	O
=	O
0.710	O
-	O
3.696	O
,	O
P=0.252	O
,	O
P=0.252	O
)	O
(	O
Table	O
4	O
)	O
.	O
The	O
combined	O
AA	O
and	O
GA	O
genotype	O
was	O
significantly	O
related	O
to	O
increased	O
susceptibility	O
to	O
DLBCL	B-arm_description
(	O
OR	O
=	O
1.684	O
,	O
95	O
%	O
CI	O
=	O
1.179	O
-	O
2.404	O
,	O
P=0.004	O
)	O
(	O
Table	O
4	O
)	O
.	O
The	O
results	O
for	O
dominant	O
and	O
recessive	O
models	O
are	O
shown	O
in	O
Table	O
4	O
.	O
As	O
no	O
statistical	O
significance	O
was	O
shown	O
in	O
the	O
dominant	O
model	O
,	O
we	O
did	O
not	O
calculate	O
the	O
FPRP	O
values	O
and	O
statistical	O
power	O
for	O
the	O
dominant	O
model	O
.	O
Positive	O
association	O
was	O
observed	O
in	O
the	O
recessive	O
model	O
and	O
GA	O
genotype	O
as	O
their	O
FPRP	O
value	O
was	O
less	O
than	O
0.2	O
(	O
shown	O
in	O
Table	O
4	O
)	O
.	O

The	O
survival	O
analysis	O
of	O
all	O
248	O
DLBCL	B-arm_description
patients	O
showed	O
that	O
the	O
patients	O
with	O
genotype	O
GA	O
/	O
AA	O
(	O
P=0.006	O
,	O
Figure	O
1A	O
)	O
and	O
the	O
combined	O
GA	O
and	O
AA	O
group	O
(	O
P=0.002	O
,	O
Figure	O
1B	O
)	O
had	O
a	O
worse	O
OS	O
than	O
patients	O
with	O
GG	B-arm_description
genotype	I-arm_description
.	O
Furthermore	O
,	O
the	O
patients	O
with	O
GA	B-arm_description
/	I-arm_description
AA	I-arm_description
genotype	I-arm_description
had	O
a	O
worse	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
in	O
comparison	O
with	O
the	O
GG	B-arm_description
patients	I-arm_description
with	O
no	O
statistical	O
significance	O
(	O
P=0.058	O
,	O
Figure	O
1C	O
)	O
,	O
however	O
,	O
the	O
combined	O
GA	B-arm_description
and	I-arm_description
AA	I-arm_description
group	I-arm_description
showed	O
worse	O
PFS	B-arm_efficacy_metric
rate	O
compared	O
with	O
the	O
GG	B-arm_description
group	I-arm_description
with	O
statistically	O
significant	O
(	B-arm_efficacy_metric
P=0.033	B-arm_efficacy_results
,	I-arm_efficacy_metric
Figure	O
1D	O
)	O
.	O
Furthermore	O
,	O
it	O
was	O
also	O
indicated	O
that	O
patients	O
with	O
A	O
allele	O
showed	O
poor	O
prognosis	O
(	O
P=0.003	O
,	O
HR	O
=	O
1.944	O
,	O
95	O
%	O
CI	O
=	O
1.247	O
-	O
3.029	O
)	O
.	O

CREBBP	O
expression	O
was	O
detected	O
in	O
63	O
patients	O
and	O
32	O
controls	O
.	O
The	O
results	O
showed	O
that	O
the	O
CREBBP	O
expression	O
was	O
remarkably	O
down	O
-	O
regulated	O
in	O
patients	O
as	O
compared	O
with	O
controls	O
(	O
P<0.001	O
,	O
Figure	O
2A	O
)	O
.	O
The	O
CREBBP	O
expression	O
of	O
patients	O
with	O
GG	O
genotype	O
was	O
down	O
-	O
regulated	O
as	O
compared	O
with	O
the	O
patients	O
with	O
GA	O
and	O
AA	O
genotype	O
(	O
P=0.016	O
and	O
0.001	O
,	O
respectively	O
,	O
Figure	O
2B	O
)	O
.	O
However	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
between	O
the	O
GA	O
and	O
AA	O
subgroups	O
(	O
P=0.134	O
,	O
Figure	O
2B	O
)	O
.	O
The	O
CREBBP	O
expression	O
was	O
down	O
-	O
regulated	O
in	O
the	O
GA	O
/	O
AA	O
subgroup	O
as	O
compared	O
with	O
the	O
GG	O
subgroup	O
(	O
P=0.002	O
,	O
Figure	O
2C	O
)	O
.	O

Based	O
on	O
the	O
median	O
of	O
CREBBP	O
mRNA	O
expression	O
value	O
,	O
63	O
DLBCL	B-arm_description
patients	O
were	O
partitioned	O
into	O
two	O
subgroups	O
,	O
the	O
low	O
CREBBP	O
expression	O
subgroup	O
and	O
the	O
high	O
CREBBP	O
expression	O
subgroup	O
.	O
The	O
results	O
indicated	O
no	O
significant	O
differences	O
between	O
the	O
patients	O
with	O
lower	O
CREBBP	O
mRNA	O
level	O
and	O
those	O
with	O
high	O
CREBBP	O
mRNA	O
level	O
in	O
OS	O
(	O
P=0.201	O
,	O
Figure	O
3A	O
)	O
and	O
PFS	O
(	O
P=0.353	O
,	O
Figure	O
3B	O
)	O
.	O